Long-term extension study for people taking belzutifan
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation clinical trials.
This study is for people who are already taking belzutifan in a related trial (LITESPARK-043) and want to continue treatment for advanced solid tumors or von Hippel-Lindau-related conditions. It tests the safety and effects of long-term use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently in a parent study that includes belzutifan and are receiving active treatment.
- You have not stopped treatment due to a serious side effect in the parent study.
- You have no ongoing serious side effect that requires hospitalization or is not stable.
- You are not currently on a break from treatment because of a side effect.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
This study tests a daily pill called belzutifan for people with a rare type of gynecologic cancer (clear cell carcinoma) that has come back or not gone away after standard treatments. The drug works by targeting a protein that helps tumors grow when oxygen levels are low.
This study gathers information from people with a rare condition called VHL (a genetic disorder that increases the risk of certain tumors) who are taking the drug belzutifan. It looks at how well the drug works and how safe it is over time.
This study tests an oral drug called belzutifan in teenagers with certain solid tumors. Belzutifan may shrink tumors by blocking a protein that helps them grow.
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
Hear when a new Von Hippel-Lindau Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.